Two Sigma Investments LP Has $8.34 Million Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Two Sigma Investments LP trimmed its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 776,901 shares of the biotechnology company's stock after selling 53,723 shares during the period. Two Sigma Investments LP owned approximately 0.92% of Anavex Life Sciences worth $8,344,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in AVXL. Nwam LLC lifted its holdings in shares of Anavex Life Sciences by 0.3% during the fourth quarter. Nwam LLC now owns 913,051 shares of the biotechnology company's stock valued at $9,806,000 after acquiring an additional 2,575 shares during the period. Northern Trust Corp increased its position in shares of Anavex Life Sciences by 1.6% during the 4th quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company's stock worth $7,592,000 after purchasing an additional 10,938 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Anavex Life Sciences by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,215 shares of the biotechnology company's stock valued at $7,273,000 after purchasing an additional 11,239 shares during the last quarter. Invesco Ltd. boosted its position in Anavex Life Sciences by 2,419.8% in the fourth quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company's stock valued at $6,606,000 after buying an additional 590,639 shares in the last quarter. Finally, Pier Capital LLC bought a new stake in Anavex Life Sciences during the fourth quarter worth about $4,746,000. Institutional investors and hedge funds own 31.55% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Monday, April 7th. D. Boral Capital reissued a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th.

Anavex Life Sciences Trading Down 0.8%

Shares of NASDAQ:AVXL traded down $0.06 during mid-day trading on Friday, reaching $7.57. The stock had a trading volume of 231,140 shares, compared to its average volume of 1,221,798. The firm has a 50 day simple moving average of $8.57 and a two-hundred day simple moving average of $9.09. The firm has a market cap of $646.27 million, a PE ratio of -13.73 and a beta of 0.82. Anavex Life Sciences Corp. has a twelve month low of $3.51 and a twelve month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same period last year, the company posted ($0.13) EPS. On average, equities analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.